Glaucoma
Conditions
Keywords
Glaucoma suspect
Brief summary
The goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants. The main questions it aims to answer are: * What are the sensitivity and specificity of VeriSee GLC for detecting glaucoma suspects based on fundus images? * How does the performance of VeriSee GLC compare with the reference standard defined by the majority consensus of three independent evaluators? Researchers will compare the screening results generated by VeriSee GLC with the reference standard to assess its diagnostic performance. This retrospective study will use previously collected fundus images. VeriSee GLC performs automated image analysis to identify glaucomatous signs, including retinal nerve fiber layer (RNFL) defects, vertical cup-to-disc ratio (VCDR) enlargement, and rim-to-disc ratio (RDR) changes. The output is intended to assist healthcare professionals in identifying glaucoma suspects for referral, rather than providing a definitive diagnosis.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
1. The adult color fundus image (aged 20 and above) 2. The requirements of color fundus image * The resolution of image is 1024 × 1024 pixels or higher; * The angle view of image is 45-or 50-degree. * Images captured from eyes with myopia not exceeding -10 diopters. 3. The color fundus image includes the optic disc and RNFL areas, and one of these areas is evaluable, as judged by the healthcare professionals.
Exclusion criteria
1. The color fundus images previously used by VeriSee GLC during the development process and pre-clinical test. 2. A color fundus image of patients with cataracts, acute angle closure glaucoma or those who have undergone retinal laser surgery. 3. The optic disc and RNFL areas in the color fundus images is invisible to determine the disease condition as judged by the healthcare professionals.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and Specificity of the VeriSee GLC for Screening Glaucoma Suspects | 1 Day | The primary outcome is the sensitivity and specificity of the VeriSee GLC in identifying glaucoma suspects based on color fundus images, compared against the reference standard defined by the majority consensus of three independent evaluators. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive Predictive Value (PPV), Negative Predictive Value (NPV), and Accuracy of VeriSee GLC for Screening Glaucoma Suspects | 1 Day | Evaluate the PPV, NPV, and overall accuracy of the VeriSee GLC in identifying glaucoma suspects relative to the reference standard. |
| Accuracy of Detection for 3 Glaucomatous Signs - VCDR and RDR | 1 Day | Assess the accuracy of VeriSee GLC in detecting three glaucomatous signs: * Vertical cup-to-disc ratio (VCDR ≥ 0.7) * Rim-to-disc ratio (RDR ≤ 0.1) * Retinal nerve fiber layer (RNFL) defect |
| Accuracy of Detection for 3 Glaucomatous Signs - RNFL Defect | 1 Day | Assess the accuracy of VeriSee GLC in detecting three glaucomatous signs: * Vertical cup-to-disc ratio (VCDR ≥ 0.7) * Rim-to-disc ratio (RDR ≤ 0.1) * Retinal nerve fiber layer (RNFL) defect |
| Dice Coefficient of Disc and Cup Contours | 1 Day | Dice coefficient measures the similarity between contours generated by VeriSee GLC and evaluator annotations. The Dice coefficient ranges from 0 (no overlap) to 1 (perfect agreement). |
Countries
Taiwan
Participant flow
Recruitment details
\[Not Specified\]
Pre-assignment details
\[Not Specified\]
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 60 years STANDARD_DEVIATION 14.7 |
| Sex: Female, Male Female | 466 Participants |
| Sex: Female, Male Male | 307 Participants |
| Spherical Equivalent | -2.7 Diopter (D) STANDARD_DEVIATION 3.1 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |